Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab
Stock Information for Tiziana Life Sciences Ltd
Loading
Please wait while we load your information from QuoteMedia.